Loading institutional data...
Loading institutional data...
Held by 276 of 5,944 reporting institutions (94th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $27.13 today, the market must believe free cash flow compounds 0.4%/yr for a decade (off $184M normalized FCF).
The market's 0.4% is more conservative than its 7-yr track record.
2-stage DCF · 0.08B shares · net debt -$112M
mean -5.0% · volatility σ 202% · implied rate exceeded in 3/6 yrs
Central path = implied 0.4%/yr growth; shaded band = ±1σ (202%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29B 100.0% | $1.17B 100.0% | $1.09B 100.0% | $786.9M 100.0% | $500.6M 100.0% | $344.9M 100.0% | $229.7M 100.0% | $105.4M 100.0% | $48.6M 100.0% |
| Cost of Revenue | $984.2M 76.4% | $913.9M 78.3% | $849.8M 78.1% | $619.6M 78.7% | $388.5M 77.6% | $274.8M 79.7% | $184.2M 80.2% | $86.0M 81.6% | $41.2M 84.8% |
| Gross Profit | $304.5M 23.6% | $253.4M 21.7% | $238.8M 21.9% | $167.3M 21.3% | $112.1M 22.4% | $70.1M 20.3% | $45.5M 19.8% | $19.4M 18.4% | $7.4M 15.2% |
| Research & Development | $9.5M 0.7% | — | — | — | — | — | — | — | — |
| Selling, General & Admin | $147.1M 11.4% | $122.0M 10.4% | $117.1M 10.8% | $98.3M 12.5% | $59.6M 11.9% | $46.7M 13.5% | $23.9M 10.4% | $15.6M 14.8% | $14.1M 29.1% |
| Total Operating Expenses | $219.2M 17.0% | $185.9M 15.9% | $176.6M 16.2% | $144.0M 18.3% | $79.8M 15.9% | $61.7M 17.9% | $35.8M 15.6% | $22.9M 21.7% | $18.4M 37.9% |
| Operating Income | $85.3M 6.6% | $67.5M 5.8% | $62.2M 5.7% | $23.3M 3.0% | $32.3M 6.5% | $8.3M 2.4% | $9.7M 4.2% | -$3.5M -3.3% | -$11.0M -22.7% |
| Other Income (Expense), net | $10.2M 0.8% | $15.7M 1.3% | $8.5M 0.8% | $1.1M 0.1% | $95K 0.0% | $331K 0.1% | -$18.2M -7.9% | -$3.4M -3.3% | -$1.5M -3.0% |
| Pretax Income | $95.4M 7.4% | $83.2M 7.1% | $70.7M 6.5% | $24.4M 3.1% | $32.4M 6.5% | $8.7M 2.5% | -$8.6M -3.7% | -$6.9M -6.5% | -$12.5M -25.6% |
| Income Tax Expense | $36.9M 2.9% | $28.9M 2.5% | $8.7M 0.8% | -$5.9M -0.8% | -$33.3M -6.7% | -$37.8M -11.0% | $12K 0.0% | -$1.8M -1.7% | -$3K -0.0% |
| Net Income | $58.5M 4.5% | $54.3M 4.7% | $62.0M 5.7% | $30.4M 3.9% | $65.8M 13.1% | $46.5M 13.5% | -$8.6M -3.7% | $661K 0.6% | -$12.5M -25.6% |
| Per Share | |||||||||
| EPS (Basic) | $0.68 | $0.59 | $0.65 | $0.33 | $0.74 | $0.54 | $-0.41 | $0.04 | $-2.37 |
| EPS (Diluted) | $0.65 | $0.57 | $0.62 | $0.30 | $0.66 | $0.47 | $-0.41 | $0.04 | $-2.37 |
| Weighted Avg Shares (Basic) | 85.7M | 91.5M | 95.0M | 92.2M | 89.1M | 85.7M | 20.7M | 5.5M | 5.7M |
| Weighted Avg Shares (Diluted) | 89.9M | 95.4M | 100.7M | 100.0M | 100.4M | 99.1M | 20.7M | 5.5M | 5.7M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
5/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $82M buybacks = $82M returned on $192M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 9 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 11%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 9 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-18
No material risks flagged.
Where each multiple sits in its own 7-yr range · 30th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 7-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 2.5× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 81.6 | 80.2 | 79.7 | 77.6 | 78.7 | 78.1 | 78.3 | 76.4 |
| Gross Profit | 18.4 | 19.8 | 20.3 | 22.4 | 21.3 | 21.9 | 21.7 | 23.6 |
| R&D | — | — | — | — | — | — | — | 0.7 |
| SG&A | 14.8 | 10.4 | 13.5 | 11.9 | 12.5 | 10.8 | 10.4 | 11.4 |
| Operating Income | -3.3 | 4.2 | 2.4 | 6.5 | 3.0 | 5.7 | 5.8 | 6.6 |
| Income Tax | -1.7 | 0.0 | -11.0 | -6.7 | -0.8 | 0.8 | 2.5 | 2.9 |
| Net Income | 0.6 | -3.7 | 13.5 | 13.1 | 3.9 | 5.7 | 4.7 | 4.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PGNY: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| PGNY | $2.3B | 41.7× | 23.8× | 1.8× | 10.4% | 23.6% | 4.5% | 11.3% | 11.3% | — | 276 |
Peers = companies sharing PGNY's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.